Asthma–Chronic Obstructive Pulmonary Diseases Overlap Syndrome Increases the Risk of Incident Tuberculosis: A National Cohort Study

Jun-Jun Yeh1,2,3, Yu-Chiao Wang4,5, Chia-Hung Kao6,7 *

1 Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, 2 Chia Nan University of Pharmacy and Science, Tainan, Taiwan, 3 Meio University, Pingtung, Taiwan, 4 Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, 5 College of Medicine, China Medical University, Taichung, Taiwan, 6 Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan, 7 Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan

* d10040@mail.cmuh.org.tw

Abstract

Purpose

The association between asthma–chronic obstructive pulmonary diseases (COPD) overlap syndrome (ACOS) and tuberculosis (TB) has yet to be studied.

Methods

The newly diagnosed TB patients (age > 20 y) treated from January 2000 to December 2008 were included (ACOS cohort, n = 10 751; non-ACOS cohort, n = 42 966). The non-ACOS cohort involved patients with confirmed absence of ACOS. We calculated incidence rate ratios (IRRs) for TB in the ACOS and non-ACOS cohorts by using poisson regression analysis. Cox proportional hazards regression models were used to determine the adjusted HR (aHR) for TB in the ACOS cohort compared with the non-ACOS cohort.

Results

The aHR for TB was 2.41 (95% confidence interval [CI], 2.19–2.66) in the ACOS cohort. The TB risk was significantly higher in the ACOS cohort than in the non-ACOS cohort when stratified by age, sex, comorbidities, and atopy. Within the ACOS cohort, the aHR was higher among patients receiving SABAs+SAMAs, LABAs+LAMAs, and ICSs (aHR [95% CI]: 3.06 [2.75–3.41], 3.68 [2.93–4.61], and 2.79 [1.25–6.22], respectively; all P < .05). Furthermore, patients with more than 15 outpatient visits and hospitalizations per year demonstrated the highest aHR (8.09; 95% CI, 6.85–9.56).

Conclusions

ACOS cohort potentially develop incident TB, regardless of the age, sex, comorbidities and atopy; even without receiving the inhalers. This risk is higher, especially in the ACOS cohort.
have a high frequency of medical services or receiving the inhalers such as SABAs +SAMAs, LABAs+LAMAs and ICSs.

Introduction

Asthma–chronic obstructive pulmonary diseases (COPD) overlap syndrome (ACOS) is clinically defined as representing either a hybrid of eosinophilic bronchiolitis [1] (asthma, typically childhood-onset, Th2-mediated inflammation, and induced sputum eosinophilia ≥ 3%) [2] and neutrophilic bronchiolitis (COPD or adult-onset asthma and Th1-mediated inflammation) [3,4] or independent clinical entities [3,4]. A previous study demonstrated that the association of the Th2 signature with increased severity and asthma-like features (eg, a favorable corticosteroid response) in ACOS suggests that Th2 inflammation is crucial for disease identification in COPD subsets with an unclear clinical history of asthma [5]. Tai et al revealed that children with severe asthma are at an increased COPD risk [6]. According to these findings, ACOS can be identified by its features shared between asthma and COPD. ACOS is being increasingly recognized [7], and its prevalence reportedly increases with age. In a 5-year follow-up study, the incidence of acute respiratory events was higher in the ACOS cohort than in the COPD cohort [8]; therefore, ACOS is a burden on hospital staff globally [9],[10].

The pharmacotherapy of ACOS [8] is similar to that of COPD and asthma [11]. The medications normally prescribed for COPD can potentially be useful in patients with critical asthma syndrome, particularly those with ACOS [12]. In the phenotype-based pharmacotherapeutic approach, bronchodilators alone are considered in patients with the nonfrequent exacerbator phenotype of COPD [13], whereas a combination of bronchodilators and inhaled corticosteroids (ICSs) [14] is considered in patients with ACOS[15] or with the moderate-to-severe exacerbator phenotype of COPD [16].

Patients with COPD may have a high frequency of longer hospital stays, thus increasing their susceptibility to nosocomial tuberculosis (TB) [17]. Anemia [18], pneumonia[18] and hypoalbuminemia [19] are predisposing factors of readmission for COPD. Patients with COPD are at a high risk of nutritional deficiency, which is associated with declines in respiratory function, lean body mass, strength, and immune function [20]. These elements [21] are also critical risk factors for TB [22,23]. Meanwhile, the smoking–related diseases (e.g. hypertension, hyperlipidemia, diabetes, pneumonia, alcohol-related illnesses, stroke, ischemic heart disease) [24], cancer [25], postinflammatory fibrosis (PPF) [26] and human immunodeficiency virus (HIV) infection [22] were potential risk factors of the TB also [25].

The ACOS may consider as a different entity [27] in the chronic airway limitations diaeases [28] and the relationship of this disorder with the TB has not been reported in the English literature. Therefore, in this study, we hypothesized that ACOS may play a role in the development of incident TB, and we tested this hypothesis by conducting a cohort study involving the general population of Taiwan.

Methods

Data Source

The National Health Insurance (NHI) program of Taiwan was established in March 1995. It consolidates 13 insurance programs by the Taiwan Department of Health, with a coverage rate of approximately 99% of the population of Taiwan since 2000. All claims data from the NHI program, including beneficiary registry, disease records, and other medical services, are
collected in the National Health Insurance Research Database (NHIRD). We used the Longitudinal Health Insurance Database 2000 (LHID2000) for establishing our study cohort. LHID2000 comprises claims data collected from one million people randomly selected from the total insurant population during 1996–2011. Taiwan’s NHI constructed this disease record system on the basis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). To ensure the privacy of the insurants, the Taiwan National Health Research Institutes uses only scrambled and anonymous numbers to indicate the files of the insurants.

Ethics Statement

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115). The IRB also specifically waived the consent requirement.

Study Population

We used a retrospective population-based cohort study design. Fig 1 shows the flow chart for selecting the study population. ACOS patients were aged >20 y and treated from January 2000 to December 2008. The ACOS cohort comprised patients with COPD (ICD-9-CM codes: 491, 492, and 496) and concurrent physician-diagnosed asthma patients (ICD-9-CM code: 493) [8]. The date of asthma diagnosis was defined as the index date. In this study, the pure COPD cohort exclude asthma component and the pure asthma cohort exclude COPD component, respectively[29]. Only, a physician diagnosis of asthma and COPD [27] in the same patient [29] enrolled in the ACOS cohort.[28] Therefore, the ACOS cohort have the nearly same number of the syndrome [29,30] with asthma and COPD (persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD), this definition in line with the syndromic approach the chronic airway limitations in Global Initiative for Asthma (GINA) report. ACOS cohort is therefore identified by the features it shares with both asthma and COPD) [11]. The non-ACOS cohort contained patients with 

![Fig 1. Process of selecting subjects for study cohorts.](doi:10.1371/journal.pone.0159012.g001)
confirmed absence of ACOS. For each patient in the ACOS cohort, 4 controls were selected using the frequency-matching method on the basis of age (at 5-y intervals), sex, and the year of the index date. We excluded patients diagnosed with TB (ICD-9-CM codes: 010–018) before the index date in both cohorts. The follow-up period was from the index date until withdrawal from the NHI, development of TB, or December 31, 2011.

The confounding factors, including age, sex, and TB-associated comorbidities, were controlled in the analysis model for adjustment. Patients with comorbidities were defined as those with a disease history before the baseline. The TB-associated comorbidities included allergic rhinitis (AR; ICD-9-CM code: 477), atopic dermatitis (AD; ICD-9-CM code: 691), allergic conjunctivitis (AC; ICD-9-CM codes: 372.05, 372.10, and 37214), hypertension (ICD-9-CM codes: 401–405), hyperlipidemia (ICD-9-CM code: 272), diabetes (ICD-9-CM code: 250), alcohol-related illnesses (ICD-9-CM codes: 291, 303, 305, 571.0, 571.1, 571.2, 571.3, and 790.3), pneumonia (ICD-9-CM codes: 480–487), ischemic heart disease (IHD; ICD-9-CM codes: 410–414), stroke (ICD-9-CM codes: 430–438), postinflammatory pulmonary fibrosis (PPF; ICD-9-CM codes: 515), cancer (ICD-9-CM codes: 140–208), and HIV infection (ICD-9-CM codes: 795,71, V08, 042, 079,53).

We also considered the medicine treatment effect of the following drugs and their combinations on the association between ACOS and TB: inhaled short-acting β-agonists (SABAs) alone, inhaled short-acting muscarinic antagonists (SAMAs) alone, a combination of inhaled SABAs and SAMAs, inhaled long-acting β-agonists (LABAs) alone, inhaled long-acting muscarinic antagonists (LAMAs) alone, and ICSs.

**Statistical Analyses**

The chi-square test was used to analyze the differences in categorical variables (sex and comorbidities) between the ACOS and non-ACOS cohorts, with the results presented as the numbers and percentages for these variables. The continuous variable (age) was analyzed using the Student t test, with the results presented as mean and standard deviation (SD). The incidence density of TB was calculated as the number of TB events divided by the sum of observation time (per 1000 person-y). In both cohorts, the incidence rate ratios (IRR) for TB and their 95% confidence intervals (95% CIs) were measured for these variables by using Poisson regression analysis. The cumulative incidence curves for the 2 cohorts were plotted using the Kaplan–Meier method, and the differences between the curves were analyzed using the log-rank test. To elucidate the TB risk, crude hazard ratios (HRs) and adjusted HRs (aHRs) and their 95% CIs were estimated using Cox proportional hazards regression models. Furthermore, the multivariable Cox proportional hazards regression model was used to estimate the TB risk on the basis of the drugs used for treatment; the model was also used to elucidate the association between frequency of outpatient visits and hospitalizations (per year) and TB risk among patients with ACOS. A 2-sided P value of <.05 was considered significant. SAS 9.4 software (SAS Institute, Cary, NC, USA) was used for data management and statistical analyses, whereas the incidence curves were plotted using R software (R Foundation for Statistical computing, Vienna, Austria).

**Results**

This study included a total of 10 751 patients with ACOS and 42 966 patients without ACOS (Table 1). After frequency matching for age and sex, we determined no significant differences between the ACOS and non-ACOS cohorts. The mean age of the patients in the ACOS cohort was 64 years (SD, 14.4; \( P = .26 \)), with most of them aged >65 years (55.1%). Nearly 55% of the patients with ACOS were men. Moreover, patients with ACOS were more likely to have TB-
associated comorbidities than were those without ACOS (all \( P < .0001 \), chi-square test) except for cancer and HIV infection. The cumulative incidence of TB in the ACOS cohort was significantly higher than that in the non-ACOS cohort (\( P < .0001 \), log-rank test; Fig 2).

During follow-up, 688 TB events (incidence rate: 9.64 per 1000 person-y) occurred in the ACOS cohort, whereas 1202 (incidence rate: 3.99 per 1000 person-y) occurred in the non-ACOS cohort. The IRR of TB in the ACOS cohort was 2.42 compared with the non-ACOS cohort (95% CI, 2.29–2.55). After controlling for age, sex and history of each comorbidity, we determined that the TB risk in the ACOS cohort was 2.41-fold higher than that in the non-ACOS cohort (aHR [95% CI], 2.41 [2.19–2.66]). Compared with those without ACOS, both men and women patients with ACOS showed increased TB risks (aHR [95% CI]: 2.26 [2.02–2.54] and 2.90 [2.38–3.53], respectively). The age-stratified analysis also revealed similar results: the TB risk was higher among patient with ACOS than among those without ACOS, regardless of the age: 20–65-year group (aHR [95% CI], 2.90 [2.35–3.60]) and \( \geq 65 \) -year group (aHR [95% CI], 2.21 [1.97–2.47]). Regarding patients without any comorbidity, the ACOS cohort demonstrated a 3.49-fold higher TB risk than did the non-ACOS cohort (95% CI, 2.61–4.66). For patients with at least one comorbidity, the aHR of TB in the ACOS cohort was 2.36 greater than that in the non-ACOS cohort (95% CI, 2.13–2.61). Compared with atopy patients

Table 1. Comparison of demographics and comorbidity between ACOS and non-ACOS cohorts.

|                  | ACOS No (N = 42966) | ACOS Yes (N = 10751) | p-value |
|------------------|---------------------|----------------------|--------|
| Sex              | n       | %     | n     | %     |        |
| Women            | 19161   | 44.6  | 4792  | 44.6  | 0.97   |
| Men              | 23805   | 55.4  | 5959  | 55.4  |        |
| Age, year        |         |       |       |       | 0.99   |
| 20–35            | 1560    | 3.63  | 390   | 3.63  |        |
| 35–65            | 17740   | 41.3  | 4435  | 41.3  |        |
| \( \geq 65 \)    | 23666   | 55.1  | 5926  | 55.1  |        |
| Mean (SD) \( ^a \) | 64.2 (14.4) | 64.6 (14.4) | 0.26 |
| Comorbidity      |         |       |       |       |        |
| AR               | 4852    | 11.3  | 3244  | 30.2  | \(< .0001 \)
| AD               | 1079    | 2.51  | 441   | 4.10  | \(< .0001 \)
| AC               | 9399    | 21.9  | 3080  | 28.6  | \(< .0001 \)
| Alcohol-related illness | 592 | 1.38 | 329 | 3.06 | \(< .0001 \)
| Diabetes         | 9568    | 22.3  | 2982  | 27.7  | \(< .0001 \)
| Hypertension     | 21166   | 49.3  | 6836  | 63.6  | \(< .0001 \)
| Hyperlipidemia   | 11603   | 27.0  | 3698  | 34.4  | \(< .0001 \)
| Pneumonia        | 8397    | 19.5  | 4161  | 38.7  | \(< .0001 \)
| IHD              | 12042   | 28.0  | 4742  | 44.1  | \(< .0001 \)
| Stroke           | 8724    | 20.3  | 3072  | 28.6  | \(< .0001 \)
| PPF              | 80      | 0.19  | 57    | 0.53  | \(< .0001 \)
| Cancer           | 1476    | 3.44  | 380   | 3.53  | 0.61   |
| HIV infection    | 8       | 0.02  | 2     | 0.02  | 0.99   |

Chi-square test
\( ^a \) Student’s t-test.
ACOS, asthma–COPD overlap syndrome; AR, allergic rhinitis; AD, atopic dermatitis; AC, allergic conjunctivitis; IHD, ischemic heart disease; PPF, postinflammatory pulmonary fibrosis.

doi:10.1371/journal.pone.0159012.t001
without ACOS, the TB risk was nearly 2-fold higher in atopy patients with ACOS (95% CI, 1.61 – 2.25) (Table 2).

Table 3 presents data for various risk factors for TB analyzed in this study. Men patients were at a higher risk of developing TB than were women patients (aHR [95% CI], 2.28 [2.05 – 2.53]). The TB risk increased with age (aHR [95% CI], 3.11 [2.77 – 3.51] for those aged ≥65 y). The TB risk was higher in patients who had comorbidity of diabetes (aHR [95% CI], 1.14

Table 2. Incidence and adjusted hazard ratio of tuberculosis stratified by sex, age, and comorbidity between ACOS and non-ACOS cohorts.

| Variables   | No | Yes | Compared to non-ACOS cohort |
|------------|----|-----|---------------------------|
| Variables  | Event | PY | Rate | Event | PY | Rate | IRR* (95% CI) | Adjusted HR† (95% CI) |
| Overall    | 1202 | 301225 | 3.99 | 688 | 71365 | 9.64 | 2.42(2.29–2.55)*** | 2.41(2.19–2.66)*** |
| Sex        |     |     |     |     |     |     |                   |                        |
| Women      | 276 | 139241 | 1.98 | 189 | 33389 | 5.66 | 2.86(2.63–3.10)*** | 2.90(2.38–3.53)*** |
| Men        | 926 | 161984 | 5.72 | 499 | 37975 | 13.1 | 2.30(2.15–2.46)*** | 2.26(2.02–2.54)*** |
| Age, year  |     |     |     |     |     |     |                   |                        |
| 20–65      | 227 | 149780 | 1.52 | 177 | 36817 | 4.81 | 3.17(2.92–3.44)*** | 2.90(2.35–3.60)*** |
| ≥65        | 975 | 151445 | 6.44 | 511 | 34547 | 14.8 | 2.30(2.15–2.46)*** | 2.21(1.97–2.47)*** |
| Comorbidity|     |     |     |     |     |     |                   |                        |
| No         | 238 | 89635 | 2.66 | 57 | 6816 | 8.36 | 3.15(2.74–3.62)*** | 3.49(2.61–4.66)*** |
| Yes        | 964 | 211590 | 4.56 | 631 | 64549 | 9.78 | 2.15(2.02–2.27)*** | 2.36(2.13–2.61)*** |
| Atopic syndrome |     |     |     |     |     |     |                   |                        |
| No         | 851 | 218178 | 3.90 | 433 | 36738 | 11.8 | 3.02(2.83–3.23)*** | 2.73(2.42–3.08)*** |
| Yes        | 351 | 83047 | 4.23 | 255 | 34626 | 7.36 | 1.74(1.60–1.90)*** | 1.91(1.61–2.25)*** |

ACOS, asthma-COPD overlap syndrome; Atopic syndromes including allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; PY, person-year; Rate, incidence rate (per 1,000 person-years); IRR*, incidence rate ratio; Adjusted HR†: multiple analysis including sex, age, comorbidity of allergic rhinitis, atopic dermatitis, allergic conjunctivitis, alcohol-related illness, diabetes, hypertension, hyperlipidemia, pneumonia, ischemic heart disease, stroke, postinflammatory pulmonary fibrosis, cancer, and HIV infection.

*p<0.05
***p<0.001.

doi:10.1371/journal.pone.0159012.t002
### Table 3. The adjusted hazard ratio of tuberculosis in different risk factors.

| Variables            | N     | Event | Crude HR (95% CI)         | Adjusted HR (95% CI)        |
|----------------------|-------|-------|---------------------------|-----------------------------|
| **ACOS**             |       |       |                           |                             |
| No                   | 42966 | 1202  | 1.00                      | 1.00                        |
| Yes                  | 10751 | 688   | 2.40(2.19–2.64)***         | 2.36(2.14–2.60)***          |
| **Sex**              |       |       |                           |                             |
| Women                | 23953 | 465   | 1.00                      | 1.00                        |
| Men                  | 29764 | 1425  | 2.62(2.36–2.91)***         | 2.28(2.05–2.53)***          |
| **Age groups, years**|       |       |                           |                             |
| 20–65                | 24125 | 404   | 1.00                      | 1.00                        |
| ≥65                  | 29592 | 1486  | 3.61(3.23–4.03)***         | 3.11(2.77–3.51)***          |
| **Comorbidity**      |       |       |                           |                             |
| AR                   |       |       |                           |                             |
| No                   | 45621 | 1621  | 1.00                      | 1.00                        |
| Yes                  | 8096  | 269   | 0.99(0.87–1.12)           | 0.79(0.69–0.90)***          |
| AD                   |       |       |                           |                             |
| No                   | 52197 | 1822  | 1.00                      | 1.00                        |
| Yes                  | 1520  | 68    | 1.50(1.18–1.91)**         | 1.24(0.98–1.59)             |
| AC                   |       |       |                           |                             |
| No                   | 41238 | 1483  | 1.00                      | 1.00                        |
| Yes                  | 12479 | 407   | 0.99(0.89–1.11)           | 0.85(0.76–0.96)**           |
| Alcohol-related illness |   |       |                           |                             |
| No                   | 52796 | 1855  | 1.00                      | 1.00                        |
| Yes                  | 921   | 35    | 1.32(0.94–1.84)           | 1.09(0.78–1.53)             |
| Diabetes             |       |       |                           |                             |
| No                   | 41167 | 1396  | 1.00                      | 1.00                        |
| Yes                  | 12550 | 494   | 1.29(1.16–1.42)***        | 1.14(1.02–1.27)*            |
| Hypertension         |       |       |                           |                             |
| No                   | 25715 | 724   | 1.00                      | 1.00                        |
| Yes                  | 28002 | 1166  | 1.67(1.52–1.83)           | 1.05(0.94–1.17)             |
| Hyperlipidemia       |       |       |                           |                             |
| No                   | 38416 | 1412  | 1.00                      | 1.00                        |
| Yes                  | 15301 | 478   | 0.88(0.80–0.98)*          | 0.74(0.66–0.83)***          |
| Pneumonia            |       |       |                           |                             |
| No                   | 41159 | 1272  | 1.00                      | 1.00                        |
| Yes                  | 12558 | 618   | 1.85(1.68–2.04)***        | 1.45(1.31–1.60)***          |
| IHD                  |       |       |                           |                             |
| No                   | 36933 | 1158  | 1.00                      | 1.00                        |
| Yes                  | 16784 | 732   | 1.56(1.42–1.71)***        | 1.02(0.92–1.13)             |
| Stroke               |       |       |                           |                             |
| No                   | 41921 | 1336  | 1.00                      | 1.00                        |
| Yes                  | 11796 | 554   | 1.77(1.60–1.95)***        | 1.19(1.07–1.33)***          |
| PPF                  |       |       |                           |                             |
| No                   | 53580 | 1875  | 1.00                      | 1.00                        |
| Yes                  | 137   | 15    | 4.37(2.63–7.26)***        | 2.54(1.53–4.23)***          |
| Cancer               |       |       |                           |                             |
| No                   | 51861 | 1827  | 1.00                      | 1.00                        |
| Yes                  | 1856  | 63    | 1.24(0.97–1.60)           | 0.99(0.77–1.28)             |

(Continued)
Table 3. (Continued)

| Variables | N      | Event | Crude HR (95% CI) | Adjusted HR (95% CI) |
|-----------|--------|-------|-------------------|----------------------|
| No        | 53707  | 1889  | 1.00              | 1.00                 |
| Yes       | 10     | 1     | 3.59 (0.51–25.3)  | 3.16 (0.45–22.5)     |

ACOS, asthma–COPD overlap syndrome; AR, allergic rhinitis; AD, atopic dermatitis; AC, allergic conjunctivitis; Adjusted HR: multiple analysis including sex, age groups, comorbidity of AR, AD, AC, alcohol-related illness, diabetes, hypertension, hyperlipidemia, pneumonia, ischemic heart disease, stroke, postinflammatory pulmonary fibrosis, cancer, and HIV infection.

*p<0.05
**p<0.01
***p<0.001.

doi:10.1371/journal.pone.0159012.t003

Table 4. Adjusted hazard ratio of tuberculosis found in the follow-up period associated with ACOS and prescriptions of SABAs, SAMAs, LAMAs, LABAs, or ICSs.

| Variables | N      | Event | Rate   | Adjusted HR (95% CI) |
|-----------|--------|-------|--------|----------------------|
| Non-ACOS cohort | 42966 | 1202  | 3.99   | 1.00                 |
| ACOS cohort |        |       |        |                      |
| Without SABAs and SAMAs | 3501 | 94    | 3.68   | 1.29 (1.05–1.60)* |
| Only used SABAs | 1568 | 54    | 4.74   | 1.56 (1.18–2.05)** |
| Only used SAMAs | 207  | 11    | 7.71   | 1.95 (1.08–3.54)* |
| Used SABAs and SAMAs | 5475 | 529   | 16.03  | 3.06 (2.75–3.41)** |
| Without LAMAs and LABAs | 8021 | 428   | 8.19   | 2.14 (1.91–2.40)** |
| Only used LAMAs | 287  | 29    | 14.79  | 2.89 (2.37–3.35)** |
| Only used LABAs | 1888 | 150   | 11.33  | 2.66 (1.84–3.85)** |
| Used LAMAs and LABAs | 555  | 81    | 20.66  | 3.68 (2.93–4.61)** |
| Without ICSs | 6697 | 376   | 8.79   | 2.15 (1.90–2.43)** |
| Used ICSs | 4054  | 312   | 10.92  | 2.79 (2.15–6.22)** |

ACOS, asthma–COPD overlap syndrome; LABA, long-acting b-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting b-agonist; SAMA, short-acting muscarinic antagonist; ICS, inhaled corticosteroid; Adjusted HR: multiple analysis including sex, age, comorbidity of allergic rhinitis, atopic dermatitis, allergic conjunctivitis, alcohol-related illness, diabetes, hypertension, hyperlipidemia, pneumonia, ischemic heart disease, stroke, postinflammatory pulmonary fibrosis, cancer, and HIV infection.

*p<0.05
***p<0.001.

doi:10.1371/journal.pone.0159012.t004
those without ACOS (95% CI, 2.75–3.41). Compared with those without ACOS, the aHRs (95% CIs) for TB were 2.89 (2.37–3.35), 2.66 (1.84–3.85), and 3.68 (2.93–4.61) in ACOS patients receiving LAMAs alone, LABAs alone, and LAMAs+LABAs, respectively. ACOS patients receiving ICSs had a 2.79-fold higher TB risk than did those without ACOS (95% CI, 1.25–6.22).

The association of TB risk with the frequency of outpatient visits and hospitalizations per year because of COPD or asthma exacerbation is presented in Table 5. When this frequency increased, the aHR for TB among the patients with ACOS also increased from 1.24 (95% CI, 1.05–1.46) for those with 3 or more visits per year to 8.09 (95% CI, 6.85–9.56) for those with more than 15 visits (P < .0001), compared with the non-ACOS cohort.

**Discussion**

A crucial finding of this study is that patients with ACOS cohort have a higher TB risk than do those without ACOS, regardless of age, sex, or comorbidities. The clinical manifestations of ACOS include in the elderly population [31] and young adult [32], early-onset asthma following steroid treatment [33], and immunocompromised condition because of corticosteroid usage at a relatively higher-than-prescribed dose [34]. These manifestations are potential risk factors for TB. Frequent intensive care unit hospitalization [8] because of recurrent and severe exacerbation of ACOS also increases the nosocomial TB risk. Therefore, even in the absence of comorbidities, ACOS is primarily a critical risk factor for TB.

The AD increased risk of the TB in the previous studies [35], probably because of immunodeficiency [35]. The current study determined that the TB risk didn’t increase in the presence of the AD. By contrast, other atopies such as AR and AC reduced the TB risk. Moreover, the relationships between allergic diseases and TB reported by von Mutius et al [36] and Flohr et al [37] are controversial. The relationship of atopic disease with the TB warrant further investigation.

We also observed that the smoking-related diseases such as diabetes were associated with the TB risk. This finding is consistent with that of Lin et al. [38] Meanwhile, pneumonia [39] and PPF [26] increased risk of the TB in line with the previous study [26,39]. Cardiovascular diseases (e.g.stroke) [8,24] are critical risk factors leading to hospitalization, thus increasing the susceptibility of patients with ACOS to nosocomial TB. By contrast, hyperlipidemia reduces the TB risk; in hyperlipidemia, the cholesterol levels are high [40], and this may prevent

### Table 5. The adjusted hazard ratio of tuberculosis associated with number of outpatient visits and hospitalizations per year due to COPD or asthma exacerbation.

| Variables | N   | Event | Rate | Adjusted HR (95% CI) |
|-----------|-----|-------|------|----------------------|
| Non-ACOS cohort | 42966 | 1202 | 3.99 | 1.00 |
| Number of outpatient visits and hospitalizations per year in ACOS cohort (n = 10751) | | | | |
| ≤ 3 | 5709 | 173 | 4.00 | 1.24(1.05–1.46)** |
| 3–7 | 2299 | 166 | 11.1 | 2.46(2.09–2.91)*** |
| 7–15 | 1778 | 178 | 17.7 | 3.17(2.70–3.73)*** |
| >15 | 965 | 171 | 56.4 | 8.09(6.85–9.56)*** |
| p-value for trend | | | | < .0001 |

ACOS, asthma–COPD overlap syndrome; Adjusted HR: multivariable analysis including sex, age, comorbidity of allergic rhinitis, atopic dermatitis, allergic conjunctivitis, alcohol-related illness, diabetes, hypertension, hyperlipidemia, pneumonia, ischemic heart disease, stroke, postinflammatory pulmonary fibrosis, cancer, and HIV infection.

**p<0.01
***p<0.001.

doi:10.1371/journal.pone.0159012.t005
malnutrition, reducing the TB risk. The other smoking-related diseases (e.g., alcohol-related illness, hypertension, IHD) and malnutrition-related diseases (e.g., cancer, HIV) didn’t increase the TB risk. The relationship of the smoking-related diseases and the malnutrition-related diseases with the TB risk in the ACOS cohort warrant further investigation.

In the current study, patients with ACOS receiving SABAs+SAMAs or LABAs+LAMAs demonstrated higher TB risk than did those receiving SABAs, SAMAs, LABAs, or LAMAs alone. During acute exacerbation of ACOS, patients receive combined therapy without ICSs [41],—either SABAs+SAMAs or LABAs+LAMAs [42]—but it does not reduce the criticality of such acute respiratory events [8], thus leading to frequent hospitalizations and increasing the patients’ susceptibility to nosocomial TB infection.

We observed that patients receiving ICSs for the severe phenotype of ACOS had a higher TB risk [43]. A high dosage or long-term use [44] of ICSs for the severe phenotype of ACOS leads to a high frequency of hospitalizations, contributing to a higher nosocomial TB risk. Patients with ACOS receiving a combined therapy containing ICSs have the highest TB risk [25]. This is corroborated by our result that higher the frequency of outpatient visits and hospitalizations, higher the TB risk.

In the Lee et al study [45], compared the 23,594 COPD cases with the 47,188 non-COPD control subjects based on the NHIRD, they found that ICSs were not independent risk factors for TB. In versa, a recent Chung et al. study based on the NHIRD also, [25] compared the 8,091 TB patients (including the 1017 asthma patients and 2,342 COPD patients) with the 32,364 non-TB patients indicated that long-term use of ICSs is associated with a 2.04-fold increased risk of developing TB. Our study agree this conclusion. This imply that the patients in the ACOS cohort [31] sharing both the asthma component and COPD component [3] in this disorder, and this cohort may be a different entity [46] in the chronic airway limitation [28]. Therefore, the ICSs play a different role on the risk of the TB in the different cohort.

Finally, even ACOS patients not receiving any inhaled bronchodilator or ICSs demonstrated high TB risk. ACOS is a combination of eosinophilic and neutrophilic bronchiolitis [47], and its asthma component is associated with mycoplasma pneumonia [48]. Therefore, airway remodeling [49] associated with epithelial desquamation as well as submucosal lymphocyte infiltration [5] may result in TB infection. In addition, high intake of oral bronchodilators [45] and high frequency of the admissions [8,34] may be factors causing the immunocompromised condition among patients with ACOS. This supports our finding that these factors in combination also contribute to the TB risk, even without receiving the inhalers.

A retrospective cohort study revealed that patients with ACOS have a significantly lower health-related quality of life, with more frequent and severe acute exacerbations, despite a relatively younger age and lower burden of cigarette smoking [32]. Similarly, our patients with ACOS appeared more likely to have a considerably lower quality of life and more frequent acute exacerbation than did patients with COPD alone. This assumption is supported by the lung tissue destruction, emphysema [50], and air trapping observed on the chest CT of patients with ACOS. Our study results may alert clinical physicians regarding the early detection of ACOS among patients with an obstructive airway disease such as COPD [8,31,51]. In addition, our patients with ACOS receiving monotherapy (SABAs, SAMAs, LABAs, LAMAs, or ICSs) or combined therapy (SABAs+SAMAs or LABAs+LAMAs) showed higher frequency of acute respiratory distress events than did those without ACOS [8]. In this study, the TB risk and frequency of outpatient visits and hospitalizations were higher in the ACOS cohort receiving the inhaled bronchodilators (SABAs+SAMAs and LABAs+LAMAs) or ICSs than in the non-ACOS cohort. Therefore, the clinical physician should be aware of the incident TB among the ACOS cohort in either the receiving the inhalers or not receiving the inhalers at the same time, regardless of the age, sex and comorbidities.
Limitations

The definition and treatment of ACOS varies in the literature. In addition, we did not include systemic steroids, antibiotics, or oral bronchodilators, such as leukotrine modifiers, phosphodiesterase-4 inhibitors, and theophylline in the analysis. Meanwhile, smoking habits, malnutrition status and environment factors were not analyzed. We only analyze the smoking-related diseases (e.g. hypertension, hyperlipidemia, diabetes, alcohol-related illnesses, pneumonia, stroke, IHD) and malnutrition-related diseases (e.g. cancer, HIV) for avoiding the bias. These confounding factors are essential and warrant investigation.

Strengths

This study included a cohort representing the general population. In Taiwan, before prescribing an inhaler, patients must be screened through the pulmonary function test (PFT), and a public nurse respiratory educates them regarding its use and avoiding the environmental factor, assess the nutrition status and evaluates the immune status. For diagnosing asthma [52] and COPD [53], the patient history, clinical manifestations, pulmonary function [53], and thoracic imaging indicate the diseases; in addition, consensus of the chest physician, rheumatologist, and immunologist [54,55] is required. After diagnosis, the inhaler [56] is prescribed under the strict policies of the NHI member. Meanwhile, under the policy of establishing a physician centered model for releasing long-term prescription and escalating public medical knowledge to prevent over-use of National Insurance Resource, we need follow up the PFT [57]. In Cheng et al study, the COPD patients received the chest-X-ray (84.7%), PFT (58.4%), and a computed tomography scan (39.4%) in accordance with this finding [58]. Hence, even the PFT were unavailable in the NHIRD. Based on these strategies, the nearly over half of all patients in the ACOS cohort receiving the PFT (e.g. coexistence of increased variability of airflow in a patient with incompletely reversible airway obstruction) [51] at least 2 times under the services of multidisciplinary team. The chest physician [54,55] must be trained by the Taiwan Society of Pulmonary and Critical Care Medicine, Taiwan Association of Asthmatics, Taiwan Association of Chronic Obstructive Pulmonary Disease, or the Chinese of Society of Immunology. Similarly, the coding of TB requires a consensus of well-trained chest specialists and infection specialists as well as review against the Centers for Disease Control and Prevention criteria. In this study, we addressed the majority of drugs used for treating ACOS. We also analyzed atopies, which play a crucial role in ACOS development. Therefore, we exclude the TB in the the patients have pure the asthmatic components or pure the COPD components. These main strengths of our study aid in discriminating patients with COPD or asthma from ACOS patients for estimating susceptibility to TB and clarifying the association of ACOS with incident TB.

Conclusions

ACOS cohort potentially develop incident TB, regardless of the age, sex, comorbidities, even without receiving the inhalers. This risk is higher, especially in the ACOS cohort have a high frequency of medical services or receiving the inhalers such as SABAs + SAMAs, LABAs + LAMAs and ICSs.

Author Contributions

Conceived and designed the experiments: JJY CHK. Performed the experiments: JJY YCW CHK. Analyzed the data: JJY YCW CHK. Contributed reagents/materials/analysis tools: CHK. Wrote the paper: JJY YCW CHK.
References

1. Miravitlles M, Soriano JB, Ancochea J, Muñoz L, Duran-Tauleria E, Sánchez G, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013; 107: 1053–1060. doi: 10.1016/j.rmed.2013.03.007 PMID: 23597591

2. Nguyen MS, Nguyen Dang D, Schleich F, Manise M, Corhay JL, Louis R. [Asthma-COPD overlap syndrome among patients with stable COPD]. Rev Med Liege 2015; 70: 37–43. PMID: 25902605

3. Ghebre MA, Bafadhel M, Desai D, Cohen SE, Newbold P, Rapley L, et al. Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015; 135: 63–72. doi: 10.1016/j.jaci.2014.06.035 PMID: 25129678

4. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) 2011; 2011: 861926.

5. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, et al. Asthma-COPD Overlap: Clinical Relevance of Genomic Signatures of Type 2 Inflammation in COPD. Am J Respir Crit Care Med. 2015; 191:758–66. doi:10.1164/rccm.201408-1458OC PMID: 25611785

6. Tai A, Tran H, Roberts M, Clarke N, Wilson J, Robertson CF. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax 2014; 69: 805–810. doi: 10.1136/thoraxjnl-2013-204815 PMID: 24646659

7. Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015; 70: 683–691. doi: 10.1136/thoraxjnl-2014-206740 PMID: 25948695

8. Chung WS, Lin CL, Kao CH. Comparison of acute respiratory events between asthma-COPD overlap syndrome and COPD patients: a population-based cohort study. Medicine (Baltimore) 2015; 94: e755.

9. Lopez-Campos JL, Agusti A. Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal. Lancet Respir Med 2015; 3: 729–734. doi:10.1016/S2213-2600(15)00242-8 PMID: 26165134

10. Nielsen M, Barnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome—a systematic review. Int J Chron Obstruct Pulmon Dis 2015; 10: 1443–1454. doi: 10.2147/COPD.S85363 PMID: 26251584

11. GINA Report GSFAMAP. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). 2015

12. Albertson TE, Schivo M, Gidwani N, Kenyon NJ, Sutter ME, Chan AL, et al. Pharmacotherapy of critical asthma syndrome: current and emerging therapies. Clin Rev Allergy Immunol 2015; 48: 7–30. doi: 10.1007/s12016-013-8393-8 PMID: 24178860

13. Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. Respir Med. 2015; 109:1031–9. doi: 10.1016/j.rmed.2015.05.012 PMID: 26094050

14. Israel E, Roche N, Martin RJ, Colice G, Dorinsky PM, Postma DS, et al. Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting beta-Agonist for Step-Up Therapy in Asthma. Ann Am Thorac Soc 2015; 12: 798–806. doi: 10.1513/AnnalsATS.201412-580OC PMID: 25756308

15. Hizawa N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis 2015; 10: 1093–1102. doi: 10.2147/COPD.S72858 PMID: 26089659

16. Montuschi P, Malerba M, Santini G, Miravitlles M. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today 2014; 19: 1928–1935. doi: 10.1016/j.drudis.2014.08.004 PMID: 25182512

17. Zetola NM, Macesic N, Shin SS, Peloso A, Ncube R, Klaasen JD, et al. Longer hospital stay is associated with higher rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan Africa. BMC Infect Dis 2014; 14: 409. doi: 10.1186/1471-2334-14-409 PMID: 25047744

18. Yu TC, Zhou H, Suh K, Arcona S. Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2015; 7: 37–51. doi: 10.2147/CEOR.S74181 PMID: 25609986

19. Chen CW, Chen YY, Lu CL, Chen SC, Chen YJ, Lin MS, et al. Severe hypoalbuminemia is a strong independent risk factor for acute respiratory failure in COPD: a nationwide cohort study. Int J Chron Obstruct Pulmon Dis 2015; 10: 1147–1154. doi: 10.2147/COPD.S85831 PMID: 26124654

20. Snijder JT, Jena AB, Lithnicum MT, Hegazi RA, Partridge JS, LaVallée C, et al. Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. Chest 2015; 147: 1477–1484. doi: 10.1378/chest.14-1368 PMID: 25357165
21. Yeh JJ, Chen SC, Chen CR, Yeh TC, Lin HK, Hong JB, et al. A high-resolution computed tomography-based scoring system to differentiate the most infectious active pulmonary tuberculosis from community-acquired pneumonia in elderly and non-elderly patients. Eur Radiol 2014; 24: 2372–2384. doi: 10.1007/s00330-014-3279-6 PMID: 24972956

22. Inghammar M, Ekborn A, Engefström G, Ljungberg B, Romanus V, Löfdahl CG, et al. COPD and the risk of tuberculosis—a population-based cohort study. PLoS ONE 2010; 5: e10138. doi: 10.1371/journal.pone.0010138 PMID: 20405056

23. Yeh JJ, Neoh CA, Chen CR, Chou CY, Wu MT. A high resolution computer tomography scoring system to predict culture-positive pulmonary tuberculosis in the emergency department. PLoS ONE 2014; 9: e93847. doi: 10.1371/journal.pone.0093847 PMID: 24727951

24. Yeh CC, Wang HH, Chou YC, Hu CJ, Chou WH, Chen TL, et al. High risk of gastrointestinal hemorrhage in patients with epilepsy: a nationwide cohort study. Mayo Clin Proc 2013; 88: 1091–1098. doi: 10.1016/j.mayocp.2013.06.024 PMID: 24012412

25. Chung WS, Chen YF, Hsu JC, Yang WT, Chen SC, Chiang JY. Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study. Int J Clin Pract 2014; 68: 1193–1199. doi: 10.1111/ijcp.12459 PMID: 24838040

26. Chung MJ, Goo JM, Im JG. Pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Eur J Radiol. 2004; 52: 175–179. PMID: 15489076

27. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge. Respirology. 2016; 21:410–8. doi:10.1111/resp.12653 PMID: 26450153

28. Papaiwannou A, Zarogoulidis P, Porpodis K, Spyratos D, Kioumis I, Pitsiou G, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis 2014; 6 Suppl 1: S146–151. doi:10.3978/j.issn.2072-1439.2014.03.04 PMID: 24672688

29. Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis. PLoS ONE 2015; 10: e0136065. doi:10.1371/journal.pone.0136065 PMID: 26336076

30. Kim MA, Noh CS, Chang YJ, Hong YK, Lee JS, Lee SW, et al. Asthma and COPD overlap syndrome is associated with increased risk of hospitalisation. Int J Tuberc Lung Dis 2015; 19: 864–869. doi: 10.5588/ijtld.14.0327 PMID: 26056115

31. Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015; 70: 683–691. doi:10.1136/thoraxjnl-2014-206740 PMID: 25948695

32. van Boven JF, Román-Rodríguez M, Palmer JF, Toledo-Pons N, Cosío BG, Soriano JB. Comorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life. Chest 2016; 149: 1011–1020. doi: 10.1016/j.chest.2015.12.002 PMID: 26836966

33. de Marco R, Marcon A, Rossi A, Antó JM, Cerveri I, Gislason T, et al. Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. Eur Respir J 2015; 46: 671–679. doi: 10.1183/09031936.0008615 PMID: 26113674

34. Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015; 3: 719–728. doi: 10.1016/S2213-2600(15)00254-4 PMID: 26255108

35. Kreins AY, Ciancanelli MJ, Okada S, Kong XF, Ramírez-Alejo N, Klici SS, et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015; 212: 1641–1662. doi: 10.1084/jem.20140280 PMID: 26304966

36. von Mutius E, Pearce N, Beasley R, Cheng S, von Ehrenstein O, Björkstén B, et al. International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema. Thorax 2000; 55: 449–453. PMID: 10817790

37. Flohr C, Nagel G, Weinmayr G, Kleiner A, Williams HC, Alt-Khaled N, et al. Tuberculosis, bacillus Calmette-Guerin vaccination, and allergic disease: findings from the International Study of Asthma and Allergies in Childhood Phase Two. Pediatr Allergy Immunol 2012; 23: 32–331. doi: 10.1111/j.1399-3038.2011.01248.x PMID: 22192272

38. Lin YH, Chen CP, Chen PY, Huang JC, Ho C, Weng HH, et al. Screening for pulmonary tuberculosis in type 2 diabetes elderly: a cross-sectional study in a community hospital. BMC Public Health 2015; 15: 3. doi: 10.1186/1471-2458-15-3 PMID: 25572102

39. Feng JY, Fang WF, Wu CL, Yu CJ, Lin MC, Ku SC, et al. Concomitant pulmonary tuberculosis in hospitalized healthcare-associated pneumonia in a tuberculosis endemic area: a multi-center retrospective study. PLoS ONE 2012; 7: e36832. doi: 10.1371/journal.pone.0036832 PMID: 22629334

40. Perez-Guzman C, Vargas MH, Quinonez F, Bazavilvazo N, Aguilar A. A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 2005; 127: 643–651. PMID: 15706008
41. Miravitlles M, Soler-Cataluna JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252–1256. doi: 10.1183/09031936.00118912 PMID: 23060631

42. Vogelmeier CF, Asijee GM, Kupas K, Beeh KM. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(R)). Adv Ther 2015; 32: 537–547. doi: 10.1007/s12325-015-0216-2 PMID: 26100349

43. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 2013; 6: 197–219. doi: 10.1586/ercp.13.2 PMID: 23473596

44. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105–1113. doi: 10.1136/thoraxjnl-2012-203175 PMID: 23749841

45. Lee CH, Lee MC, Shu CC, Lim CS, Wang JY, Lee LN, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013; 13: 194. doi: 10.1186/1471-2334-13-194 PMID: 23631563

46. Tho NV, Park HY, Nakano Y. Asthma–COPD overlap syndrome (ACOS): A diagnostic challenge. Respirology 2016; 21: 410–418. doi: 10.1111/resp.12653 PMID: 26450153

47. Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 2015; 136: 531–545. doi: 10.1016/j.jaci.2015.05.052 PMID: 26343937

48. Yeh JJ, Wang YC, Hsu WH, Kao CH. Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study. J Allergy Clin Immunol 2016; 137: 1017–1023 e1016. doi: 10.1016/j.jaci.2015.09.032 PMID: 26586037

49. Salazar-Peláez LM, Abraham T, Herrera AM, Correa MA, Paré PD, et al. Vitronectin expression in the airways of subjects with asthma and chronic obstructive pulmonary disease. PLoS ONE 2015; 10: e0119717. doi: 10.1371/journal.pone.0119717 PMID: 25768308

50. Gelb AF, Yamamoto A, Verbeken EK, Nadel JA. Unraveling the pathophysiology of the asthma-copd overlap syndrome: Unsuspected mild centrilobular emphysema is responsible for loss of lung elastic recoil in never smokers with asthma with persistent expiratory airflow limitation. Chest 2015; 148: 313–320. doi: 10.1378/chest.14-2483 PMID: 25950858

51. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2015; 65: 728–735. doi: 10.1136/thoraxjnl-2015.205106 PMID: 26385366

52. Ao WC, Lin YS, Caffrey JL, Lin MH, Hsu HT, Myers L, et al. Higher body mass index may induce asthma among adolescents with pre-asthmatic symptoms: a prospective cohort study. BMC Public Health 2011; 11: 1–8. doi: 10.1186/1471-2458-11-1 PMID: 21199570

53. Lo C, Liang WM, Hang LW, Wu TC, Chang YJ, Chang CH, et al. A psychometric assessment of the St. George’s respiratory questionnaire in patients with COPD using Rasch model analysis. Health Qual Life Outcomes 2015; 13: 131. doi: 10.1186/s12955-015-0320-7 PMID: 26290330

54. Huang JY, Jian ZH, Ndi Nfor O, Jhang KM, Ku XY, Ko PC, et al. The Impact of Coexisting Asthma, Chronic Obstructive Pulmonary Disease and Tuberculosis on Survival in Patients with Lung Squamous Cell Carcinoma. PLoS ONE 2015; 10: e0133367. doi: 10.1371/journal.pone.0133367 PMID: 26196516

55. Wei YF, Kuo PH, Tsai YH, Tao CW, Cheng SL, Lee CH, et al. Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD—subgroup analysis of the Taiwan obstructive lung disease cohort. Int J Chron Obstruct Pulmon Dis 2015; 10: 1951–1956. doi: 10.2147/COPD.S88114 PMID: 26392770

56. Huang WC, Tsai YH, Wei YF, Kuo PH, Tao CW, Cheng SL, et al. Wheezing, a significant clinical phenotype of COPD: experience from the Taiwan Obstructive Lung Disease Study. Int J Chron Obstruct Pulmon Dis 2015; 10: 2121–2126. doi: 10.2147/COPD.S92062 PMID: 26504377

57. Chiang CH, Liu SL, Chuang CH, Jiang YH. Effects of guideline-oriented pharmacotherapy in patients with newly diagnosed COPD: a prospective study. Wien Klin Wochenschr 2013; 125: 353–361. doi: 10.1007/s00508-013-0362-y PMID: 23817861

58. Cheng SL, Chan MC, Wang CC, Lin CH, Wang HC, Hsu JY, et al. COPD in Taiwan: a National Epidemiology Survey. Int J Chron Obstruct Pulmon Dis. 2015; 10: 2459–2467. doi: 10.2147/COPD.S89672 PMID: 26648708